Physician profile
Scott Barttelbort
NPI 1235249665
$2,643.20
in general payments reported to CMS, 2019-2025
9 companies · $72.48 in 2025
The $72.48 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $121 · 2021: $774 · 2022: $505 · 2023: $465 · 2024: $143 · 2025: $72.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $678.04 | 2019-2022 | |
| Merz North America, INC. | $615.88 | 2019-2025 | |
| Galderma Laboratories, L.P. | $508.86 | 2019-2025 | Dysport |
| Tela Bio, INC. | $266.07 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Allergan, INC. | $195.04 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $171.40 | 2019 | |
| Revance Therapeutics, INC. | $127.61 | 2024-2025 | Daxxify |
| Abbvie INC. | $58.08 | 2023-2024 | Natrelle Saline-Filled Breast Implants |
| Ethicon US, LLC | $22.22 | 2023 | Dermabond Prineo, Stratafix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Barttelbort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.